HIBADH抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10714(HIBADH Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The HIBADH (β-hydroxyisobutyryl-CoA deacylase) antibody is a tool used to study the HIBADH enzyme, which plays a critical role in the branched-chain amino acid (BCAA) catabolism pathway, specifically in the metabolism of L-valine. HIBADH catalyzes the hydrolysis of β-hydroxyisobutyryl-CoA to free CoA and β-hydroxyisobutyrate, a key step in mitochondrial BCAA degradation. Dysregulation of HIBADH has been linked to metabolic disorders, mitochondrial dysfunction, and certain cancers, highlighting its importance in cellular energy homeostasis and disease pathogenesis.

The HIBADH antibody is typically developed for detecting endogenous HIBADH protein in research applications, such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). It aids in investigating tissue-specific expression patterns, subcellular localization, and protein abundance under various physiological or pathological conditions. Recent studies have explored its potential role in metabolic syndromes, cancer progression, and neurodegenerative diseases, where altered BCAA metabolism may contribute to disease mechanisms.

Commercially available HIBADH antibodies are often validated for specificity using knockout cell lines or siRNA-mediated knockdown to ensure minimal cross-reactivity. Researchers utilize these antibodies to uncover HIBADH's regulatory networks, interaction partners, and post-translational modifications, advancing understanding of its biological functions and therapeutic relevance.